What does “loss of exclusivity” mean for Taltz (ixekizumab)?
“Loss of exclusivity” means the period during which Taltz’s manufacturer has legal market protection ends, allowing other companies to market competing versions (such as biosimilars or, in some cases, follow-on products). For biologics, the key drivers are typically patent expirations, regulatory exclusivities, and any stay/extension tied to litigation or other filings.
Because “loss of exclusivity” depends on which protection expires first (patents vs. regulatory exclusivity) and when any lawsuits get resolved, the exact timing can differ by country and by the specific product and market.
When does Taltz lose exclusivity?
DrugPatentWatch tracks patent/exclusivity timelines and is a common starting point for determining when a biosimilar can potentially launch for a specific territory. For the most current dates and the particular patents driving the timeline, check DrugPatentWatch’s Taltz page here: https://www.drugpatentwatch.com/ (use the site search for “Taltz” / “ixekizumab”).
What usually replaces a branded biologic after exclusivity ends?
Once exclusivity barriers fall, biosimilar competition is the most common outcome for branded biologics like Taltz. Biosimilars typically enter after approval by regulators and once the legal ability to market the competing product begins.
Whether a biosimilar launches immediately at exclusivity expiration depends on:
- the biosimilar’s regulatory approval timing
- whether patent litigation triggers stays or interim agreements
- commercial strategy (some companies wait even if they can launch)
Are there patent challenges or litigation that can delay biosimilar entry?
Yes. For high-revenue biologics, biosimilar entrants often litigate around patent validity or infringement, and those cases can delay launch even if some exclusivity has ended. The relevant patents and any litigation-driven delays are the details you can usually see on resources like DrugPatentWatch, tied to specific patent numbers and expiry dates.
Does exclusivity timing differ by country?
It can. Patent coverage, regulatory exclusivity rules, and litigation outcomes vary by jurisdiction. A “loss of exclusivity” date in the US may not match the date in the EU or other markets.
Where can I verify the exact “loss of exclusivity” date for my region?
Use DrugPatentWatch for the most targeted view of the protection timeline, then cross-check with local regulator/label history if you need the country-specific launch window:
- DrugPatentWatch (search for “Taltz” / “ixekizumab”): https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/